We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

80 hedge funds and large institutions have $200M invested in Avadel Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

309% more call options, than puts

Call options by funds: $6.67M | Put options by funds: $1.63M

63% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 16

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

5% more funds holding

Funds holding: 76 → 80 (+4)

0.09% less ownership

Funds ownership: 56% → 55.91% (-0.09%)

32% less capital invested

Capital invested by funds: $294M → $200M (-$93.9M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
80
Holders Change
+4
Holders Change %
+5.26%
% of All Funds
1.39%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
26
Reduced
16
Closed
7
Calls
$6.67M
Puts
$1.63M
Net Calls
+$5.04M
Net Calls Change
+$409K

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.89M
2
BIP
Brandes Investment Partners
California
+$2.43M
3
WP
Woodline Partners
California
+$1.85M
4
TLP
Tri Locum Partners
New York
+$1.22M
5
Morgan Stanley
Morgan Stanley
New York
+$1.21M

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$4.24M
2
BlackRock
BlackRock
New York
-$3.85M
3
ACM
Asymmetry Capital Management
California
-$2.48M
4
California Public Employees Retirement System
California Public Employees Retirement System
California
-$1.06M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$902K
Name Holding Trade Value Shares
Change 		Change in
Stake
EGM
51
Engineers Gate Manager
New York
$93K +$110K +13,800 New
BSW
52
Buckingham Strategic Wealth
Missouri
$92K – – –
D.E. Shaw & Co
53
D.E. Shaw & Co
New York
$92K +$108K +13,636 New
JF
54
Jump Financial
Illinois
$92K +$109K +13,712 New
UBS Group
55
UBS Group
Switzerland
$91K +$52.5K +6,616 +96%
Envestnet Asset Management
56
Envestnet Asset Management
Illinois
$90K +$106K +13,316 New
LWAM
57
Legacy Wealth Asset Management
Minnesota
$87K +$103K +13,000 New
ProShare Advisors
58
ProShare Advisors
Maryland
$71K +$83.3K +10,494 New
ACM
59
ACT Capital Management
Pennsylvania
$71K +$83.4K +10,500 New
Osaic Holdings
60
Osaic Holdings
Arizona
$69K -$7.94K -1,000 -9%
KAS
61
Kestra Advisory Services
Texas
$67K – – –
ED
62
Exane Derivatives
France
$60.5K – – –
TRCT
63
Tower Research Capital (TRC)
New York
$58K +$43.9K +5,530 +186%
CHA
64
Carmichael Hill & Associates
Maryland
$54K – – –
WAM
65
Wolverine Asset Management
Illinois
$52K – – –
CLOS
66
Compagnie Lombard Odier SCmA
Switzerland
$40K – – –
LFG
67
Larson Financial Group
Missouri
$27K – – –
Citigroup
68
Citigroup
New York
$24K +$19.3K +2,427 +218%
PCH
69
Polar Capital Holdings
United Kingdom
$18.8K – – –
PCM
70
Penserra Capital Management
California
$8K +$40 +5 +0.4%
BCV
71
Banque Cantonale Vaudoise
Switzerland
$7K – – –
Barclays
72
Barclays
United Kingdom
$4K -$108K -13,595 -95%
BWP
73
Baldwin Wealth Partners
Massachusetts
$3K – – –
PNC Financial Services Group
74
PNC Financial Services Group
Pennsylvania
$3K +$3.97K +500 New
SPIA
75
Steward Partners Investment Advisory
New York
$2K -$114K -14,302 -98%
1 2
3
4

AVDL Hedge Fund Activity: Q2 2021 in Review

80 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2021, worth a combined $200M — down 32% from $294M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AVDL positions and 7 closed out — a net gain of 4 holders — while 26 added to existing stakes and 16 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $3.89M. The largest seller was Acuta Capital Partners, cutting an estimated $4.24M.

  • 80 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2021, up from 76 in Q1 2021.
  • Funds reported $200M of Avadel Pharmaceuticals stock for Q2 2021, down 32% quarter-over-quarter.
  • 11 funds opened new Avadel Pharmaceuticals positions in Q2 2021 and 7 closed out, a net change of +4 holders.
  • The largest Avadel Pharmaceuticals buyer in Q2 2021 was Janus Henderson Group, an estimated $3.89M added.
  • The largest Avadel Pharmaceuticals seller in Q2 2021 was Acuta Capital Partners, an estimated $4.24M sold.

Based on aggregated 13F filings for Q2 2021.